Abstract Aim: This pharmacovigilance study analyzed echinocandin-related adverse events (AEs) using the FDA Adverse Event Reporting System (FAERS) database to identify agent-specific safety signals and inform clinical decision-making. Methods: AE reports were extracted from FAERS covering Q1 2004 to Q4 2025. Four disproportionality algorithms—reporting odds ratio (ROR), proportional reporting ratio (PRR), information component (IC025), and empirical Bayesian geometric mean (EBGM05)—were applied.
